Bristol Myers Squibb, JnJ stop Phase 3 Librexia ACS trial evaluating milvexian Ruchika Sharma16 Nov 2025 3:30 PM ISTPrinceton: Bristol Myers Squibb in collaboration with Johnson & Johnson has announced the decision to stop the Phase 3 Librexia ACS...
Evotec gets USD 5 m milestone payment from Bristol Myers Squibb Ruchika Sharma13 Nov 2025 12:30 PM ISTHamburg: Evotec SE has announced that it has received a USD 5 m milestone payment from Bristol Myers Squibb, following the acceptance of an...
Alembic Pharma bags USFDA nod for blood cancer drug Dasatinib Ruchika Sharma7 Nov 2025 2:54 PM ISTVadodara: Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug Administration...
Alembic Pharma gets USFDA okay for Triamcinolone Acetonide Injectable Suspension Ruchika Sharma22 Oct 2025 12:30 PM ISTVadodara: Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New...
Bristol myers Squibb to acquire Orbital for USD 1.5 billion Ruchika Sharma12 Oct 2025 2:00 PM ISTPrinceton: Bristol Myers Squibb and Orbital Therapeutics have announced a definitive agreement under which Bristol Myers Squibb will acquire...
Bristol Myers Squibb BMS 986446 gets USFDA fast track designation for Alzheimer's Disease Ruchika Sharma6 Oct 2025 12:15 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446,...
Lupin bags USFDA approval for Multiple myeloma treatment Ruchika Sharma17 Sept 2025 6:19 PM ISTMumbai: Global pharma major Lupin Limited has announced that the company has received approval from the United States Food and Drug Administration...
Zydus, Synthon enter licensing, supply agreement for multiple sclerosis drug Ozanimod for US market Ruchika Sharma4 Sept 2025 5:56 PM ISTAs one of the first filers, Synthon has received tentative approval within 30 months from USFDA.
Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan for previously treated Advanced EGFR Mutated Non Small Cell Lung Cancer Ruchika Sharma19 Aug 2025 2:15 PM ISTPrinceton: SystImmune Inc., a clinical-stage biotechnology company, and Bristol Myers Squibb have announced that the U.S. Food and Drug...
Bristol Myers Squibb Breyanzi application accepted for priority review by USFDA for Marginal Zone Lymphoma Ruchika Sharma5 Aug 2025 12:20 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license...
Bristol Myers Squibb, Bain Capital form new biopharmaceutical company - NewCo Ruchika Sharma29 July 2025 12:30 PM ISTPrinceton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, NewCo, focused on...
CDSCO Panel Approves Phase IV Protocol Amendment for Bristol-Myers Squibb's Mavacamten Study Parthika Patel24 July 2025 6:49 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has...
